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Background
Oncogenic activation and HIF-1 overexpression stimu-
late glycolysis in part by activating the bifunctional
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases
(PFKFB1-4) that synthesize fructose-2,6-bisphosphate
(F2,6BP), an allosteric activator of 6-phosphofructo-1-
kinase (PFK-1), which is an essential control point in
the glycolytic pathway. Although PFKFB3 is considered
the dominant source of F2,6BP due to its high kinase
activity and expression in multiple tumor types, the
activity and function of the other PFKFBs has not been
fully explored. Interestingly, the PFKFB4 family member
was recently found in two independent and unbiased
RNAi-based screens to be required for cancer cell survival.
We sought to examine the specific requirements of
PFKFB4 in regulating glycolytic flux relative to the pentose
shunt, two pathways required for cell survival.
Methods
Recombinant human PFKFB4 was synthesized and exam-
ined for activity. PFKFB4 protein expression was measured
by Western blotting after inhibition with siRNA. For
NMR, cells were grown in 13C-labeled glucose and spectra
captured for analysis. Xenograft experiments were
conducted.
Results
We first sought to examine the kinase and phosphatase
activities of human recombinant PFKFB4, which have
not previously been determined. We expressed and puri-
fied human PFKFB4 and found that the enzyme was
bifunctional: Km (fructose-6-phosphate, F6P) = 374.2±
20 μM; Km (F2,6BP) = 43.52± 5 μM; kinase:phosphatase
ratio = 4.6:1. We then silenced PFKFB4 using siRNA in 4
human cancer cell lines (H460, A549, LNCaP and
HCT116, scrambled siRNA as control) and found that
PFKFB4 knockdown significantly decreased the steady-
state [F2,6BP], [ATP] and 13C-glycolytic flux to lactate and
glutamate. Importantly, the requirement of PFKFB4 for
13C-glycolytic flux to lactate was significantly enhanced
under hypoxic conditions. We did not observe any effects
of PFKFB4 inhibition on flux through the oxidative
pentose shunt as measured by the conversion of
13C-glucose into purine and pyrimidine riboses and by
steady-state concentration of NAPDH. Last, we found
that PFKFB4 inhibition suppressed H460 xenograft
[F2,6BP], glucose uptake and growth in athymic mice.
Conclusions
These data indicate that PFKFB4 has greater kinase than
phosphatase activity and predominantly functions to
synthesize F2,6BP and activate glycolytic flux into the
3-carbon portion of the glycolytic pathway. This is not
surprising given that the concentration of the substrate for
the kinase reaction (F6P) is several thousand-fold higher
than the substrate for the phosphatase reaction (F2,6BP)
in normal and transformed cells. Lastly, we believe that
the increased requirement of PFKFB4 for the regulation of
glycolysis in response to hypoxia indicates that small
molecule inhibitors of PFKFB4 may have utility as
anti-neoplastic agents.
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